8-K - Apogee Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Apogee Therapeutics, Inc. entered into an Underwriting Agreement on March 24, 2026, with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC as representatives of the Underwriters to issue and sell 5,000,000 shares of common stock at $70.00 per share. The Underwriters exercised in full their option for an additional 750,000 shares, with net proceeds expected to be approximately $377.4 million after discounts and expenses.

Key Takeaways

1Entered Underwriting Agreement on March 24, 2026, for 5,000,000 Firm Shares at $70.00 per share

2Underwriters exercised full 30-day option for 750,000 additional Optional Shares on March 25, 2026

3Net proceeds from Offering, including full Option exercise, expected at $377.4 million

4Offering pursuant to shelf registration statement File No. 333-281503, effective August 12, 2024

5Expected closing on March 26, 2026

6Company agreed to indemnify Underwriters against certain liabilities under the Securities Act

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting A

Material Agreement

$70.00$377.4M

9.01

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT INDEX Exhibit No. Description 1.1 Underwriting Agreement, dated as of March 24, 2026, by and among Apog

Exhibits Only

Transaction Details

Material Agreement

Agreement: Underwriting Agreement
Parties: Apogee Therapeutics, Inc., Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC

•Issue and sell 5,000,000 shares of common stock, par value $0.00001 per share, at public offering price of $70.00 per share
•30-day option to purchase up to 750,000 additional shares at public offering price less underwriting discounts and commissions, exercised in full on March 25, 2026
•Net proceeds expected to be approximately $377.4 million after deducting Underwriters’ discounts, commissions, and estimated offering expenses
•Offered pursuant to shelf registration statement File No. 333-281503, effective August 12, 2024
•Final prospectus supplement filed March 25, 2026; expected closing March 26, 2026
•Agreement to indemnify Underwriters against certain liabilities under Securities Act of 1933, as amended

Exhibits (3)

1.1

EXHIBIT 1.1

5.1

EXHIBIT 5.1

8-K

FORM 8-K